Medifocus Inc. Announces Exclusive Agreement With Major Academic Medical Center to License Technology to Develop Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy

COLUMBIA, MD and TORONTO, ON MDFZF, MFS, OTCQX, TSX VENTURE,(Marketwired Oct 15, 2015) Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer, today announced that the Company has formally entered into an exclusive license agreement with Duke University regarding Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy. The exclusive license agreement pertains to the Patent Rights of a Duke invention for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases. The technology, described in the agreement as a method for selective expression of therapeutic genes in cancer cells by hyperthermia, provides the design basis for an adenoviral gene delivery construct that releases IL-12 upon activation by the temperature rise caused by fo


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: